J3405 HCPCS code: Injection, onasemnogene abeparvovec-brve, per treatment
J3405 is the HCPCS Level II code for injection, onasemnogene abeparvovec-brve, per treatment. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2026-07-01 |
| Last action effective | 2026-07-01 |
What changed for J3405
- July 2026: Code appears in this HCPCS release
- 2026-07-01: J3405 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J3405?
J3405 is the HCPCS Level II code for injection, onasemnogene abeparvovec-brve, per treatment. Short descriptor: "Inj onase abepar-brve treat".
Does Medicare cover J3405?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J34 codes
- J3400 — Injection, triflupromazine hcl, up to 20 mg
- J3401 — Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml
- J3402 — Injection, remestemcel-l-rknd, per therapeutic dose
- J3403 — Revakinagene taroretcel-lwey, per implant
- J3404 — Injection, zopapogene imadenovec-drba suspension, per therapeutic dose
- J3406 — Injection, omidubicel-onlv, per therapeutic dose
- J3410 — Injection, hydroxyzine hcl, up to 25 mg
- J3411 — Injection, thiamine hcl, 100 mg
- J3415 — Injection, pyridoxine hcl, 100 mg
- J3420 — Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
- J3424 — Injection, hydroxocobalamin, intravenous, 25 mg
- J3425 — Injection, hydroxocobalamin, intramuscular, 10 mcg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J3405
- Watch J3405 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J3405
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.